Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and its Active Moiety Debio 1452, Administered Orally in Healthy Subjects

Presented at ICAAC 2015, San Diego, CA, USA

F. Wittke (1), V. Nicolas-Métral (1), A. Ménétrey (1), A. Hussaini (2), B. Hafkin (3)

(1) Debiopharm International SA, Lausanne, Switzerland

(2) PAREXEL, Baltimore, MD, USA

(3) Nobelex Biotech Inc., Toronto, ON, Canada